Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$196.98 USD

196.98
213,967

-0.57 (-0.29%)

Updated Aug 26, 2024 10:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

AbbVie (ABBV) Up 9.7% Since Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Abbvie's Uterine Fibrosis Candidate Meets Goal in Study

    AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.

      Novartis Psoriasis Drug Cosentyx Positive in SCALP Study

      Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.

        AbbVie Presents New Data on Upadacitinib for Crohn's Disease

        AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

          AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan

          AbbVie (ABBV) announces a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board.

            Lilly's Taltz Positive in Phase III Label Expansion Study

            Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.

              Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning

              Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning

                Sweta Killa headshot

                5 Solid Dividend Growth Stocks Amid Rising Rates

                Dividend growth stocks pose strong fundamentals and are lucrative, especially given the new tax legislation in the United States, rising yields and heightened volatility.

                  Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis

                  Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

                    FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up

                    Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.

                      Add These 7 GARP Stocks to Your Portfolio for Better Returns

                      Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

                        Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre

                        Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.

                          Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View

                          Centene's (CNC) fourth-quarter earnings were hurt by higher selling, general & administrative expenses.

                            Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses

                            Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.

                              The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

                              The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

                                Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft

                                Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.

                                  AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018

                                  AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.

                                    Tirthankar Chakraborty headshot

                                    5 Top Earnings Growth Stocks to Buy in February

                                    We have shortlisted 5 top-rated stocks that have striking earnings growth and positive estimate revisions.

                                      Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?

                                      Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.

                                        Will Gilead (GILD) Disappoint Investors in Q4 Earnings?

                                        Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi

                                          While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.

                                            Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance

                                            Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.

                                              Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View

                                              Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.

                                                The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton

                                                The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton

                                                  Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX

                                                  Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.